The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Dual-payload antibody-drug conjugates (dp-ADCs) are being developed to address tumor heterogeneity, payload resistance, and other limitations of single-drug ADCs. By combining payloads with orthogonal or complementary mechanisms, dp-ADCs have the potential to enhance efficacy, overcome drug-resistance, and improve drug safety. However, success requires validation of safety and efficacy for the payloads, synergy for payload pairing where payload ratio, conjugation sites, linker properties, and release kinetics must be carefully designed and optimized. 

In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms. She will connect biological rationale with the complicate designs of dp-ADC, including payload ratio, conjugation sites, hydrophilic linker design, and controlled payload release. She will also discuss CMC strategies that ensure the success of an innovative dp-ADC from concepts to a clinical product. Key learning objectives for the webinar include:

1. Understanding how rational dual-payload design can address the limitations of single-payload ADCs
2. Sharing key considerations for a dp-ADC design, including payload ratio, conjugation sites, hydrophilic linker design, and controlled release
3. Exploring CMC strategies for ensuring product quality when managing complex molecule such as dp-ADC

A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.

Produced with support from: